Scientist warns over pandemic flu vaccine 6-month time lag

April 27, 2009

New research published today (Monday April 27) from the University of Leicester and University Hospitals of Leicester NHS Trust warns of a six-month time lag before effective vaccines can be manufactured in the event of a pandemic flu outbreak.

By that time, the first wave of pandemic flu may be over before people are vaccinated, says Dr Iain Stephenson, Consultant in Infectious Diseases at the Leicester Royal Infirmary and a Clinical Senior Lecturer at the University of Leicester.

In his paper published in PNAS- Proceedings of the National Academy of Sciences of the USA- Dr Stephenson makes the first case for a pre-pandemic vaccine to mitigate the worst effects of pandemic flu.

He said: "This study is the first to show an effective pre-pandemic vaccine approach. This means that we could vaccinate people potentially many years before a pandemic, to generate memory cells that are long lasting and can be rapidly boosted by a single dose of vaccine when needed."

Dr Stephenson, of the Department of Infection, Immunity and Inflammation at the University of Leicester, said: "If an influenza pandemic occurs, vaccination will to be the main way to protect the population. The major current threat seems to be from avian influenza H5N1 (bird flu) which has spread rapidly around the world and causes human infections and deaths.

"Unfortunately, if a pandemic occurs, it will take up to six months to manufacture effective vaccine, so the first waves of the pandemic may be over before people are vaccinated. Furthermore, most people need two doses of H5 pandemic vaccine to get protection- so this adds a further delay.

"To reduce any delay, we could consider stockpiling vaccine or immunizing people with vaccine prepared in advance -(a so called 'pre-pandemic vaccine' - to protect them before a future pandemic.

"However, we don't know which strain of influenza will cause the pandemic. There are several strains of H5N1 virus, so we can't be sure of which virus strain to make pre-pandemic vaccine from. Therefore a 'pre-pandemic' vaccine needs to give cross protection to as many H5 strains as possible."

Dr Stephenson and his team conducted a study comparing the effect of a single H5 bird flu vaccine dose to people who had been vaccinated with an H5 vaccine previously with people who had not previously received vaccine. The aim was the test out the idea of a pre-pandemic vaccination approach.

He said: "We found that those people who received H5 vaccine between 1999 and 2001 responded very well to a single dose of a newer H5 vaccine. They had memory cells that gave a rapid protective response within 7 days of the repeat vaccine. Also the response was very broad and able to protect against all known strains of H5N1 virus.

"In contrast, those people who had not been previously vaccinated with H5 vaccine, behaved as we had expected. They required 2 doses of vaccine and got good antibody responses up to 6 weeks after the first dose."

Dr Stephenson added that this was the first study to show an effective pre-pandemic vaccine approach.

The trial subjects were all recruited at the University of Leicester or University Hospitals of Leicester.
-end-
NOTE TO NEWSDESK:For more information, please contact Dr Stephenson via University of Leicester press office -0116 252 2415
Email: iain.stephenson@uhl-tr.nhs.uk

The authors:

Grazia Galli; Monia Bardelli; Carmine Malzone; Flora Castellino; Giuseppe Del Giudice; Michaela Praus; Angelika Banzhoff; Volker Brauer
Novartis Vaccines

Kathy Hancock; Joshua DeVos; Jacqueline Katz
Centers for Disease Control and Prevention

Katja Hoschler; Maria Zambon
Health Protection Agency

Chiara Gentile; Emanuele Montomoli
University of Siena

Teresa McNally; Karl Nicholson; Iain Stephenson
University of Leicester

Please cite University of Leicester and Leicester Royal Infirmary in any report

University of Leicester

Related Influenza Articles from Brightsurf:

Predicting influenza epidemics
Researchers at Linköping University, Sweden, have developed a unique method to predict influenza epidemics by combining several sources of data.

Common cold combats influenza
As the flu season approaches, a strained public health system may have a surprising ally -- the common cold virus.

Scent-sensing cells have a better way to fight influenza
Smell receptors that line the nose get hit by Influenza B just like other cells, but they are able to clear the infection without dying.

New antivirals for influenza and Zika
Leuven researchers have deployed synthetic amyloids to trigger protein misfolding as a strategy to combat the influenza A and Zika virus.

Assessment of deaths from COVID-19, seasonal influenza
Publicly available data were used to analyze the number of deaths from seasonal influenza deaths compared with deaths from COVID-19.

Obesity promotes virulence of influenza
Obesity promotes the virulence of the influenza virus, according to a study conducted in mice published in mBio, an open-access journal of the American Society for Microbiology.

Influenza: combating bacterial superinfection with the help of the microbiota
Frenc researchers and from Brazilian (Belo Horizonte), Scottish (Glasgow) and Danish (Copenhagen) laboratories have shown for the first time in mice that perturbation of the gut microbiota caused by the influenza virus favours secondary bacterial superinfection.

Chemists unveil the structure of an influenza B protein
MIT chemists have discovered the structure of an influenza B protein called BM2, a finding that could help researchers design drugs that block the protein and help prevent the virus from spreading.

How proteins help influenza A bind and slice its way to cells
Researchers have provided new insight on how two proteins help influenza A virus particles fight their way to human cells.

Eating elderberries can help minimize influenza symptoms
Conducted by Professor Fariba Deghani, Dr. Golnoosh Torabian and Dr.

Read More: Influenza News and Influenza Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.